1.Appendix one; proficiency testing programs. ASHI laboratory manual. 2nd ed.American Society for Histocompatibility and Immunogenetics;1990. p. 693–8.
2.Shroyer TW. Proficiency testing. Nikaein A, editor. ASHI laboratory manual. 3rd ed.American Society for Histocompativility and Immunogenetics;1996. p. VI.8.1–VI.8.3.
3.Park MH. A questionnaire survey of HLA laboratories in Korea (1993). J Korean Soc Transplant. 1993. 7:245–8. (박명희. 전국 HLA 검사실 현황 설문조사(1993). 대한이식학회지 1993;7: 245-8.).
4.Park MH., Yang YS. A questionnaire survey of HLA laboratories in Korea (1995). Korean J Clin Pathol. 1996. 16:987–1000. (박명희및 양윤선. 전국 HLA 검사실 현황 설문조사(1995). 대한임상병리학회지 1996;16: 987-1000.).
5.Park MH., Whang DH. A questionnaire survey of HLA laboratories in Korea (1997). Korean J Clin Pathol. 1998. 18:650–9. (박명희 및황동희. 전국 HLA 검사실현황설문조사(1997). 대한임상병리학회지 1998;18: 650-9.).
6.Park MH., Whang DH., Kim BC. A two-year study on the HLA typing proficiency survey in Korea, 1996-1998. Korean J Clin Pathol. 1999. 19:714–22. (박명희, 황동희, 김병철. HLA 검사 신빙도조사 결과(1996-1998년). 대한임상병리학회지 1999;19: 714-22.).
7.Park MH., Kim BC., Han BY. Results of the HLA typing proficiency survey in Korea, 2000-2002. Korean J Lab Med. 2005. 25:329–39. (박명희, 김병철, 한복연. HLA 검사 신빙도조사 결과(2000-2002년). 대한진단검사의학회지 2005;25: 329-39.).
8.Lim JH., Hwang SH., Oh HB. HLA typing proficiency survey in Korea, 2003-2004. Korean J Lab Med. 2005. 25:434–41. (임지훈, 황상현, 오흥범. HLA 검사 신빙도조사 결과(2003-2004년). 대한진단검사의학회지 2005;25: 434-41.).
9.Lim JH., Hwang SH., Oh HB. A questionnaire survey of HLA laboratories in Korea (2005). Korean J Lab Med. 2005. 25:425–33. (임지훈, 황상현, 오흥범. 전국 HLA 검사실 현황 설문조사(2005). 대한진단검사의학회지 2005;25: 425-33.).
10.Neisig A., Melief CJ., Neefjes J. Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. J Immunol. 1998. 160:171–9.
11.Neefjes JJ., Ploegh HL. Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association. Eur J Immunol. 1988. 18:801–10.
12.Marrari M., Duquesnoy RJ. Progress report on the ASHI/CAP Proficiency Survey Program in Histocompatibility Testing. I. HLA-A, B, C typing, antibody screening, and lymphocytotoxicity crossmatching. American Society for Histocompatibility and Immunogenetics. College of American Pathologists. Hum Immunol. 1994. 39:87–95.
13.Van Kampen CA., Roelen DL., Versteeg-van der Voort Maarschalk MF., Hoitsma AJ., Allebes WA., Claas FH. Activated HLA class-I reactive cytotoxic T lymphocytes associated with a positive historical crossmatch predict early graft failure. Transplantation. 2002. 74:1114–9.
14.Halloran PF., Wadgymar A., Ritchie S., Falk J., Solez K., Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation. 1990. 49:85–91.
15.Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant. 2001. 16:897–904.
16.Conca R., Pratico-Barbato L., Dall'Omo AM., Amoroso A. The Italian quality control scheme for crossmatching procedures and HLA sera screening: the 2002 pilot study. Arch Pathol Lab Med. 2005. 129:1470–5.
Article
17.Duquesnoy RJ., Marrari M. Multilaboratory evaluation of serum analysis for HLA antibody and crossmatch reactivity by lymphocytotoxicity methods. Arch Pathol Lab Med. 2003. 127:149–56.
Article